Participation in Clinical Trials High Among Cancer Survivors Who Self-identify as Gay, Lesbian and Bisexual
October 29, 2012
- Association is not explained by other demographic differences.
- According to the researchers, their data should be interpreted cautiously.
SAN DIEGO — Cancer survivors who self-identified as being lesbian, gay or bisexual were more than twice as likely as heterosexual cancer survivors to have participated in cancer clinical trials, according to data from a small study presented at the Fifth AACR Conference on The Science of Cancer Health Disparities, held here Oct. 27-30, 2012.
“The data from which our findings were derived were incredibly limited. We have to interpret these data cautiously,” said Jennifer M. Jabson, M.P.H., Ph.D., a postdoctoral research fellow in the department of community health sciences at Boston University School of Public Health.
In 2011, the Institute of Medicine (IOM) issued a report titled “The Health of Lesbian, Gay, Bisexual and Transgender People: Building a Foundation for Better Understanding,” in which it identified this community as medically underserved. Jabson and colleagues studied the representation of the lesbian, gay and bisexual community in cancer clinical trials to add to existing knowledge about their experience with cancer and their participation in the clinical trial system.
The researchers used data from the Behavioral Risk Factor Surveillance System and an optional module that assesses cancer survivor participation in cancer clinical trials. They collected data from five states — Massachusetts, New Mexico, Wisconsin, Alaska and California — that used this module and an item asking self-identified lesbian, gay and bisexual status. The total population was 4,339 people.
“We thought there would be an under-representation of lesbian, gay and bisexual individuals in the data,” Jabson said. “We only found one prior paper that had been published in the last 10 years on the topic, and it found that individuals in this community were more often excluded in all clinical trials, not just those specific to cancer.”
However, the results of this study indicated that 12.5 percent of the cancer survivor population that self-identified as being lesbian, gay and bisexual participated in clinical trials compared with 6 percent of the heterosexual cancer survivor population. When adjusting the data to account for participants’ age, sex, education, race/ethnicity and survey location, cancer survivors from the lesbian, gay and bisexual community were more than twice as likely to report participation in a clinical trial.
Jabson said it is difficult to infer an explanation for these findings.
“We need to replicate our findings in a larger and more comprehensive sample to explore some of the causal or explanatory variables and to make sure that the result was not an artifact of the sample,” she said. “In addition, we agree with the IOM report that sexual orientation should be collected as a demographic variable in population-based health surveillance systems and cancer registries.”
Additional studies are warranted to explain the greater representation of individuals who self-identify as lesbian, gay and bisexual in cancer survivor clinical trials and potentially to identify ways to prevent and treat cancer in this community, according to Jabson.
# # #
Follow the AACR on Twitter: @aacr #aacr
Follow the AACR on Facebook: http://www.facebook.com/aacr.orgAbout the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 17,000 attendees. In addition, the AACR publishes seven peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the scientific partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer.
For more information about the AACR, visit www.AACR.org
(215) 446-7109Jeremy.Moore@aacr.org In San Diego, Oct. 27-30: